• SPX
  • $5,948.71
  • 0.53 %
  • $31.60
  • DJI
  • $43,870.35
  • 1.06 %
  • $461.88
  • N225
  • $38,283.85
  • 0.68 %
  • $257.68
  • FTSE
  • $8,236.80
  • 1.07 %
  • $87.53
  • IXIC
  • $18,972.42
  • 0.03 %
  • $6.28
Reneo Pharmaceuticals, Inc. (RPHM) Stock Price, News & Analysis

Reneo Pharmaceuticals, Inc. (RPHM) Stock Price, News & Analysis

Currency in USD Disclaimer

NA

NA

NA

Day's range
$1.68
Day's range
$18.2
50-day range
$1.68
Day's range
$17.5
  • Country: US
  • ISIN: US75974E1038
52 wk range
$1.68
Day's range
$82.9
Notice: This company has been marked as potentially delisted and may not be actively trading.


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 14.16
  • Piotroski Score 2.00
  • Grade Neutral
  • Symbol (RPHM)
  • Company Reneo Pharmaceuticals, Inc.
  • Price $18.20
  • Changes Percentage (952.02%)
  • Change $16.47
  • Day Low $1.68
  • Day High $18.20
  • Year High $82.90

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 11/11/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $0.00
  • High Stock Price Target $0.00
  • Low Stock Price Target $0.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$2.17
  • Trailing P/E Ratio -0.77
  • Forward P/E Ratio -0.77
  • P/E Growth -0.77
  • Net Income $-77,388,000

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Reneo Pharmaceuticals, Inc. Frequently Asked Questions

  • What were the earnings of RPHM in the last quarter?

    In the last quarter Reneo Pharmaceuticals, Inc. earnings were on Tuesday, August, 13th. The Reneo Pharmaceuticals, Inc. maker reported -$0.16 EPS for the quarter, beating analysts' consensus estimates of -$0.17 by $0.01.

  • What is the Reneo Pharmaceuticals, Inc. stock price today?

    Today's price of Reneo Pharmaceuticals, Inc. is $18.20 — it has increased by +952.02% in the past 24 hours. Watch Reneo Pharmaceuticals, Inc. stock price performance more closely on the chart.

  • Does Reneo Pharmaceuticals, Inc. release reports?

    Yes, you can track Reneo Pharmaceuticals, Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Reneo Pharmaceuticals, Inc. stock forecast?

    Watch the Reneo Pharmaceuticals, Inc. chart and read a more detailed Reneo Pharmaceuticals, Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is Reneo Pharmaceuticals, Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Reneo Pharmaceuticals, Inc. stock ticker.

  • How to buy Reneo Pharmaceuticals, Inc. stocks?

    Like other stocks, RPHM shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Reneo Pharmaceuticals, Inc.'s EBITDA?

    Reneo Pharmaceuticals, Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Reneo Pharmaceuticals, Inc.’s financial statements.

  • What is the Reneo Pharmaceuticals, Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is 0, which equates to approximately 0.00%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Reneo Pharmaceuticals, Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Reneo Pharmaceuticals, Inc.'s financials relevant news, and technical analysis. Reneo Pharmaceuticals, Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Reneo Pharmaceuticals, Inc. stock currently indicates a “sell” signal. For more insights, review Reneo Pharmaceuticals, Inc.’s technical analysis.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.